Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study Meeting Abstract
| Authors: | Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; Taylor, M.; Spilliopoulou, P.; Bendell, J.; Jaeger, D.; Chan, E.; Antonia, S. J.; Ascierto, P. A.; Hennicken, D.; Tschaika, M.; Azrilevich, A.; Rosenberg, J. |
| Abstract Title: | Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study |
| Meeting Title: | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 4 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2016 Nov 9-13 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2016-12-08 |
| Start Page: | 91 |
| Language: | English |
| DOI: | 10.1186/s40425-016-0191-4 |
| PROVIDER: | manual |
| PMCID: | PMC5260784 |
| Notes: | Meeting Abstract: O3 -- Late-breaking abstract |
Altmetric
Citation Impact
BMJ Impact Analytics
